The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

Blood

Volumn 122, Issue 1, 2013, Pages 83-92

  Shayegi, Nona ^a   Kramer, Michael ^a   Bornhäuser, Martin ^a   Schaich, Markus ^a   Schetelig, Johannes ^a   Platzbecker, Uwe ^a   Röllig, Christoph ^a   Heiderich, Caroline ^b   Landt, Olfert ^c   Ehninger, Gerhard ^a   Thiede, Christian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b AgenDix GmbH   (Germany)

^c TIB MOLBIOL Syntheselabor GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANTILEUKEMIC AGENT; CD135 ANTIGEN; LOCKED NUCLEIC ACID; NUCLEOPHOSMIN; ANTINEOPLASTIC AGENT; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; BONE MARROW; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; STANDARD; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; FEMALE; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-ABL; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84883677161     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-461749     Document Type: Article

References (39)

1. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074-3080. (Pubitemid 29200800)
2. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911-1918. (Pubitemid 27019637)
3. Falini B, Mecucci C, Tiacci E, et al GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254-266. (Pubitemid 40110814)
4. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27(3):263-270. (Pubitemid 32201846)
5. Byrd JC, Mrózek K, Dodge RK, et al; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
6. Grimwade D, Hills RK, Moorman AV, et al National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
7. Falini B, Mecucci C, Saglio G, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica. 2008;93(3):439-442. (Pubitemid 351398646)
8. Chan WY, Liu QR, Borjigin J, Busch H, Rennert OM, Tease LA, Chan PK. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry. 1989;28(3):1033-1039. (Pubitemid 19058676)
9. Chang JH, Olson MO. Structure of the gene for rat nucleolar protein B23. J Biol Chem. 1990;265(30):18227-18233.
10. Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92(4):519-532. (Pubitemid 350144298)
11. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol. 2009;27(4):171-181.
12. Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol. 2009;21(6):573-581.
13. Falini B, Bolli N, Shan J, et al. Both carboxyterminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107(11):4514-4523. (Pubitemid 43801380)
14. Bolli N, De Marco MF, Martelli MP, et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia. 2009;23(3):501-509.
15. Le Arber DA. Acute myeloid leukemia (AML) and related precursor neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. Geneva, Switzerland: WHO Press; 2008 Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.
16. Schlenk RF, Döhner K, Krauter J, et al German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-1918. (Pubitemid 351620111)
17. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733-3739. (Pubitemid 41739006)
18. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(10):4011-4020. (Pubitemid 43726809)
19. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005;106(8):2854-2861. (Pubitemid 41510764)
20. Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res. 2006;66(6):3310-3316.
21. Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103-1108. (Pubitemid 43797304)
22. Chou WC, Tang JL, Wu SJ, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia. 2007;21(5):998-1004.
23. Papadaki C, Dufour A, Seibl M, et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol. 2009;144(4):517-523.
24. Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29(19):2709-2716.
25. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114(11):2220-2231.
26. Thiede C, Creutzig E, Illmer T, Schaich M, Heise V, Ehninger G, Landt O. Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping. Leukemia. 2006;20(10):1897-1899. (Pubitemid 44575005)
27. Ritter M, Thiede C, Schäkel U, et al. Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation. Br J Haematol. 1997;98(4):969-972. (Pubitemid 27421643)
28. Verweij PJ, Van Houwelingen HC. Crossvalidation in survival analysis. Stat Med. 1993;12(24):2305-2314.
29. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data (Wiley Series in Probability and Statistics). New York, NY: Wiley; 1980.
30. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
31. Cheson BD, Bennett JM, Kopecky KJ, et al International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
32. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327(8476):307-310. (Pubitemid 16134762)
33. Brüggemann M, Raff T, Flohr T, et al German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116-1123. (Pubitemid 43156313)
34. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood. 2010;116(13):2295-2303.
35. Sockel K, Wermke M, Radke J, et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica. 2011;96(10):1568-1570.
36. Swoboda RK, Somasundaram R, Caputo L, et al. Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient. Int J Cancer. 2010;127(5):1124-1130.
37. Liso A, Colau D, Benmaamar R, et al. Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. Leukemia. 2008;22(2):424-426. (Pubitemid 351250548)
38. Greiner J, Yoko O, Hofmann S, et al. The mutated region of cytoplasmatic nucleophosmine 1 (NPM1) elicits both CD4+ and CD8+ T cell responses. 53rd Annual Meeting of the American Society of Hematology, December 10-13, 2011, San Diego, CA. Abstract 2569.
39. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-1062. (Pubitemid 29451802)